Background Most prostate cancers are characterized by a significant rise in the production of serum prostate-specific antigen (PSA), which is used widely in screening for prostate cancer. Within New Zealand, PSA is measured on automated immunoassay analysers, including models by Abbott Laboratories (Architect i2000) and Roche Diagnostics (Elecsys 2010). These assays produce similar, but not identical, results.
Introduction
Serum prostate-speci¢c antigen (PSA) is a protease produced predominantly by epithelial cells of the prostate. Most prostate cancers are characterized by a signi¢cant rise in the production of serum PSA. PSA concentrations may also be raised in cases of benign prostatic hyperplasia, with transient rises in cases of prostatitis. A small proportion of PSA is absorbed into the blood stream, where it is largely bound to either anti-chymotrypsin or a-macroglobulin, leaving only a small proportion of free uncomplexed PSA. 1 The concentrations of total and free PSA have been studied in three ethnic groups within New Zealand: New Zealand Europeans, Maori and Paci¢c Islanders. 2 This study arose from the need to determine whether the results derived from the ethnicity study were dependent on the particular PSA method.
In New Zealand, total PSA is usually measured by automated immunoassay analysers. The available assays are Architect i2000 or AxSYM from Abbott Laboratories, Elecsys 2010 or E-170 from Roche Diagnostics and ACS-180 or Centaur from Bayer. These assays produce similar, but not identical, results. Blijenberg et al. 3 showed di¡erences between assays even when the same calibrator was used. Forest et al. 4 compared results from the Roche Elecsys2010 with those from the Abbot AxSYM and found them to be di¡erent. We were therefore unable to make recommendations for PSA in New Zealand populations from data derived from the Roche Elecsys 2010 alone; test-speci¢c data was needed. We aimed to compare the measurement of PSA in New Zealand men on the Roche Elecsys 2010 with the Abbott Architect i2000, in order to determine whether they were signi¢cantly di¡erent.
Materials and methods
This study was part of a broader study of prostate disease^the Wellington Region Community Prostate Study (WRCPS)^carried out at the Wellington
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School of Medicine and Health Sciences, University of Otago. The WRCPS is a cross-sectional study which tested PSA concentrations in Maori, Paci¢c Island and European New Zealand men. From January 2000 to February 2002 a total of 1425 participants aged 40^70 years, with no history of prostate cancer or surgery for benign prostatic hyperplasia, were recruited into the WRCPS. Blood was taken; serum was separated and stored at 7308C in a number of aliquots. In order to compare assay measurements the power calculation was as follows. With 120 compared samples, the study would have a 95% con¢dence interval on the standard deviation of the di¡erence (SD) of 0.89SD, 1.15SD There would then be more than a 99% chance of ¢nding a signi¢cant di¡erence between the Abbott and the Elecsys if they are di¡erent by the amount found by Blijenberg et al. 3 (for screening a di¡erence of 0.13 and a SD of 0.17).
We randomly selected a subset (200) of the 1425 samples already tested on the Roche Elecsys 2010 assay. We did not expect the di¡erences in PSA measurement between assays to depend on age or ethnicity; therefore, a simple random sample was used and deemed likely to provide a reasonable coverage of PSA intervals by chance.
This subset of samples also had the PSA concentrations measured on the Abbott Architect i2000 system. The two di¡erent assay results were compared and the statistical relationship between them analysed.
Testing
Initial laboratory blood analysis for PSA was carried out on all 1425 samples at Capital Coast Health Laboratories (Wellington, New Zealand) using an Elecsys 2010 analyser (Roche Diagnostics, Mannheim, Germany). The 200 selected samples were sent, frozen, to another local laboratory (Medical Laboratory^Wellington, Wellington, New Zealand) where the serum PSA concentration was measured on the Abbott Architect i2000 analyser (Abbott Diagnostics Ltd, Auckland, New Zealand). Assays were performed according to the manufacturers' speci¢cations. The inter-assay coe¤cient of variation near the traditional cut-o¡ point of 4.0 ng/mL was less than 3.5% in both assays. Between-assay precision for the Elecsys and Architect, at near 4.0 ng/mL, was 4.2% and 4.8%, respectively. The functional sensitivity for both assays was 0.05 ng/mL.
Analysis
Six Abbott Architect i2000 serum PSA results were unavailable for comparison. Therefore, analysis was carried out on the ¢nal sample of 194 serum samples (from 104 European, 41 Maori and 49 Paci¢c Island subjects).
Statistical analyses were performed using SPSS version 10.1 (SPSS Inc, Chicago, Illinois, USA). Further, statistical comparisons were performed using Method Validator. 5 Because PSA was found to have a log-normal distribution, the logarithm of PSA was used in the calculation of mean values. The antilogged PSA results are reported.
The paired data were grouped into three subgroups, based on the result of the Roche Elecsys 2010 (PSA 52.5, 2.5^54.0, and 54.0 ng/mL). The number of samples in each subgroup was 171, 14 and 9, respectively. Analyses were conducted for each group.
Di¡erences in medians and log means were calculated for the paired data. The results from the two methods were analysed initially with simple linear regression analysis and then with weighted Deming analysis, and the Passing^Bablok and Bland^Altman methods. 5^7
Results
The results from the two sets of PSA analyses were found to be highly correlated (rˆ0.993). However, the slope of the regression line (with the Architect i2000 test result as the dependent variable and the Elecsys 2010 test result as the independent variable) was less than 1.0, with estimates ranging from 0.85 (weighted Deming) to 0.89 (Passing^Bablok). The intercepts in all cases were between 70.1 and 0 (see Fig. 1 ).
The outcomes of the Elecsys 2010 PSA and the Architect i2000 PSA analyses are shown in Table 1 . The Elecsys 2010 PSA result ranged from 0.0 to 13.92 ng/mL, with a median value of 0.85 ng/mL (log mean 1.31, SD 1.61). The Architect i2000 PSA ranged from 0.0 to 12.36 ng/mL, with a median value of 0.65 ng/mL (log mean 1.08, SD 2.06).
Bland-Altman di¡erence analysis gave a mean di¡erence between the results of 70.231 when the absolute results were compared, while log-transformed data gave a mean di¡erence of 70.116 (see Fig. 2 ).
Grouped by the Elecsys 2010 PSA results (PSA 52.5, 2.5^54.0, 54.0 ng/mL), a strong linear relationship continued to be seen between the Elecsys 2010 and the Architect i2000. With Elecsys 2010 PSA results 52.5 ng/mL (nˆ172 pairs), the correlation coe¤cient (r) was 0.954; with results ranging between 2.5 and 54.0 ng/mL (nˆ13 pairs), rˆ0.833; and ¢nally, with results 54.0 ng/mL (nˆnine pairs), rˆ0.993 (see Table 2 ).
The Architect i2000 produced PSA values that were 0.14 ng/mL less at the median concentration than the Elecsys 2010 values. In the region measured by the Roche assay as between 3.0 and 6.0 ng/mL (around the traditional cut-o¡ point), the mean di¡erence was 70.65 ng/mL. One serum sample in our data set gave a value of 410.0 ng/mL in the Elecsys 2010 data set (10.44 ng/mL) but a lower value in the Architect i2000 data set (9.20 ng/mL).
The slopes and intercepts from the di¡erent comparison methods are given in Table 3 . The linear and Passing^Bablok methods produced similar slopes and intercepts, whereas the weighted Deming produced a di¡erent slope.
If we take the ranges determined in the larger study for the three ethnic groups 3 and multiply them by the factor determined above, a set of ranges appropriate for the Abbott Architect i2000 analyser become apparent. We used the Passing^Bablok slope and intercept (0.886, 70.088) to determine the calculated ranges appropriate for the Architect i2000 assay (see Table 4 ). Original ranges as determined in the full study 3 were adjusted for method variation to give estimates of the range on Abbott Architect i2000 analyser. PSAˆprostate-speci c antigen.
Discussion
Our data show that the PSA values of the Elecsys 2010 and Architect i2000 assays, while highly correlated in all the PSA concentration intervals (52.5, 2.5^54.0 and 54.0 ng/mL), do not give the same result. The Architect i2000 assay overall provided results 11% lower than the Elecsys 2010-derived results. There is no reason to assume that one is more accurate than the other; however, users of the assays must be aware of these di¡erences. Reference intervals for serum PSA concentrations have been a problem for many years. The original reference range (0.0^4.0 ng/mL) was obtained using 99th percentile values of 472 men using the initial Hybritech kit. Many of these subjects were under 50 years of age. 8 This range has become almost universally accepted, whereas age-related reference intervals are now becoming widespread. Even with the advent of the age-related reference intervals, however, follow-up of a PSA result with a free PSA estimation is usually based on the initial PSA concentration being between 4.0 and 10.0 ng/mL. 9 Regardless, the widespread use of these intervals assumes that all PSA assays give the same result and that the same range can apply. The data presented here suggest that assays, even if highly correlated, do not have a 1:1 relationship. In 1998, PSA assays were a mixture of polyclonal-and monoclonal-based measurements, often using di¡erent standards. Today, however, most methods use only monoclonal reagents and standards based on the 90:10 calibrator developed at Stanford. 10 Despite these commonalties, we have shown that between two common automated PSA assays, the results in the clinically relevant range vary by more than 10%.
The di¡erences between the Elecsys 2010 and Architect i2000 assay measurements are of su¤cient magnitude that PSA results from these assays are not interchangeable. Two clinical situations might be a¡ected. The ¢rst would concern an initial PSA result where clinical decision must be based on assay methodology. Second, for individual patients PSA should be monitored by the same assay system. If this is impossible, clinicians must be cognisant of the di¡erence between the assays.
When the PSA concentration is between the assay detection limit and 2.5 ng/mL, assay measurement di¡erence might a¡ect the management decision concerning recurrent disease or assessing response to therapy. When the PSA concentration is 2.5^4.0, or 54.0 ng/mL, measurement di¡erence could a¡ect the consideration of diagnosis or therapeutic options. However, when the PSA concentration is more than 10.0 ng/mL, a small di¡erence in PSA value has little clinical importance. 11 Research has found that the statistical method used may have an in£uence on the validity of regression estimates. 12^14 Therefore, we compared a standard linear regression with weighted Deming regression and Passing^Bablok statistical methods to determine the most accurate regression estimate for our comparison study.
Simple linear regression assumes that there is no error in the x axis and that there is a constant error in the y variable, whereas the Deming regression assumes variance in both measurements. 6 These can be either a constant error (unweighted version) or an error that varies with the concentration (weighted Deming regression). Passing^Bablok regression is a non-parametric method in which the regression line is the median of all possible lines. It also assumes a constant ratio of the variances. 7 For immunoassays in which the analyte range is greater than 10-fold, the error cannot be assumed to be constant and a weighted procedure has been found to be best. 6, 7 In our comparison study, as the range of analyte values varied from 0.17 to 14.0 ng/mL, the absolute error across the range and the coe¤cient of variation would be unlikely to be constant. Therefore, we performed a weighted Deming statistical analysis, which allows for variation in error, and a Passing^B ablok analysis, which handles outliers in the most appropriate fashion. Unexpectedly, these two statistical tests gave di¡erent estimations of the slope (0.848 and 0.886). The ¢nal results were derived from the Passing^Bablok technique, because it is less susceptible to outliers.
Conclusion
In New Zealand, methodological di¡erences in terms of PSA reference intervals have not been considered signi¢cant. This comparison of PSA results from the Roche Elecsys 2010 with the Abbott Architect i2000 shows that one must take into account these di¡erences and that intervals should be validated for any particular method. Because values used for further clinical investigation and intervention may di¡er by 11%, it is important for clinicians to be aware of which testing methodology is being used. New Zealand laboratories could indicate this on report forms, drawing to attention the potential discrepancy from traditional accepted reference intervals.
